NASDAQ:XLRN Acceleron Pharma (XLRN) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free XLRN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$178.75▼$178.7550-Day Range$172.08▼$179.6852-Week Range$108.82▼$189.99VolumeN/AAverage Volume572,759 shsMarket Capitalization$10.93 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Acceleron Pharma alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Acceleron Pharma Stock (NASDAQ:XLRN)Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… XLRN Stock News HeadlinesFebruary 27, 2024 | benzinga.comORBIMED CAPITAL GP II LLC's Net WorthOctober 20, 2023 | investing.comXLRN Historical DataMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.April 15, 2023 | thestreet.comBrexit Bargain Buys: 14 More Stocks Picked by Morgan StanleyMarch 17, 2023 | reuters.comAstellas Pharma IncDecember 14, 2022 | finance.yahoo.comAcceleron Corp Becomes a Digital Correspondent BankNovember 30, 2022 | finance.yahoo.comPharma Contract Sales Market Report 2022-2032November 21, 2022 | reuters.comMerck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugsMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…October 10, 2022 | msn.comCentre Piece Of Merck's $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular TrialMay 23, 2022 | seekingalpha.comLiquidia slumps as United, MannKind get FDA nod for rival therapyJanuary 20, 2022 | thestreet.com19 Charts to Calm Your Recession FearsDecember 22, 2021 | finance.yahoo.comXLRN May 2022 140.000 putNovember 22, 2021 | finance.yahoo.comMerck Closes Biggest Biotech Deal of the YearNovember 22, 2021 | seekingalpha.comMerck announces completion of Acceleron Pharma acquisitionNovember 21, 2021 | nasdaq.comMerck's (NYSE:MRK) Balance Sheet Can Easily Handle Acquisitions like Acceleron Pharma (NASDAQ: XLRN)November 17, 2021 | apnews.comAvoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate OfferNovember 17, 2021 | nasdaq.comNotable Wednesday Option Activity: XLRN, LOW, ZGNXNovember 17, 2021 | finance.yahoo.comMerck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.November 17, 2021 | seekingalpha.comMerck says HSR waiting period for Acceleron Pharma deal expiresNovember 15, 2021 | gurufocus.comAvoro Capital Advisors LLC Buys Acceleron Pharma Inc, Apellis Pharmaceuticals Inc, Aadi ...November 15, 2021 | gurufocus.comWestern Standard LLC Buys IHS Markit, Acceleron Pharma Inc, Marlin Business Services Corp, ...November 12, 2021 | finance.yahoo.comSome Acceleron Investors Want a Better Deal From MerckNovember 12, 2021 | msn.comIs Merck's Planned Acquisition of Acceleron in Trouble?November 9, 2021 | finance.yahoo.comAvoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate OfferNovember 4, 2021 | chron.comAcceleron: Q3 Earnings SnapshotNovember 4, 2021 | finance.yahoo.comAcceleron Reports Third Quarter 2021 Financial ResultsSee More Headlines Receive XLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:XLRN CUSIPN/A CIK1280600 Webwww.acceleronpharma.com Phone(617) 649-9200Fax617-649-9988Employees312Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-166,030,000.00 Net Margins-226.01% Pretax Margin-225.99% Return on Equity-32.11% Return on Assets-29.45% Debt Debt-to-Equity RatioN/A Current Ratio12.14 Quick Ratio12.14 Sales & Book Value Annual Sales$92.52 million Price / Sales118.15 Cash FlowN/A Price / Cash FlowN/A Book Value$11.74 per share Price / Book15.23Miscellaneous Outstanding Shares61,156,000Free Float60,116,000Market Cap$10.93 billion OptionableOptionable Beta0.13 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesHabib J. DablePresident, Chief Executive Officer & DirectorLisa WymanVice President-OperationsKevin F. McLaughlinChief Financial Officer, Treasurer & Senior VPRavindra KumarChief Scientific Officer & Senior Vice PresidentJay T. BackstromExecutive VP & Head-Research & DevelopmentKey CompetitorsBio-TechneNASDAQ:TECHRepligenNASDAQ:RGENQiagenNYSE:QGENNeurocrine BiosciencesNASDAQ:NBIXVaxcyteNASDAQ:PCVXView All Competitors XLRN Stock Analysis - Frequently Asked Questions How were Acceleron Pharma's earnings last quarter? Acceleron Pharma Inc. (NASDAQ:XLRN) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.18. The biopharmaceutical company had revenue of $34.20 million for the quarter, compared to analyst estimates of $35.39 million. Acceleron Pharma had a negative trailing twelve-month return on equity of 32.11% and a negative net margin of 226.01%. The business's quarterly revenue was up 51.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.66) EPS. What is Habib Dable's approval rating as Acceleron Pharma's CEO? 11 employees have rated Acceleron Pharma Chief Executive Officer Habib Dable on Glassdoor.com. Habib Dable has an approval rating of 100% among the company's employees. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acceleron Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN). This page (NASDAQ:XLRN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acceleron Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.